Seres Therapeutics, Inc. (MCRB) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 26.42M USD. 52-week range 2.42 to 29.98 USD. Trailing P/E 11.7. Data as of 2026-10-09.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP ...